Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2012
11/22/2012WO2012156351A1 Epha4 is a disease modifier in motor neuron disease
11/22/2012WO2012156319A1 Novel anti-redness active agent and cosmetic compositions comprising same
11/22/2012WO2012156312A1 Pharmaceutical combination for use in the treatment of diabetes type 2
11/22/2012WO2012156308A1 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
11/22/2012WO2012156299A1 Lixisenatide as add-on therapy to basal insulin in type 2 diabetes
11/22/2012WO2012156298A1 Lixisenatide and metformin for treatment of diabetes type 2
11/22/2012WO2012156296A1 Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
11/22/2012WO2012155780A1 Branched-peg modified glp-1 analogue and pharmaceutically acceptable salts thereof
11/22/2012WO2012155328A1 Composition comprising endostatin and rnai molecules and the use thereof
11/22/2012WO2012155212A1 Method of treating excessive collagen formation
11/22/2012WO2012135868A3 Compositions and methods for the treatment and prevention of cardiac ischemic injury
11/22/2012WO2012135010A3 Osmotic mediated release synthetic nanocarriers
11/22/2012WO2012131676A4 Method for treating disorders of the skin
11/22/2012WO2012129228A3 Novel retro-inverso leptin peptide antagonists
11/22/2012WO2012126441A3 Cyclic peptides with an anti-neoplasic and anti-angiogenic activity
11/22/2012WO2012125720A3 Polypeptides having immunoactivating activity and methods of producing the same
11/22/2012WO2012122107A3 Apparatus, system, and method for creating biologically protected/enhanced spaces in vivo
11/22/2012WO2012108960A3 Ghrelin mimetic polypeptide hapten immunoconjugates having improved solubility and immunogenicity and methods of use thereof
11/22/2012WO2012103187A3 Methods of diagnosing and treating age-related macular degeneration
11/22/2012WO2012102645A3 Pharmaceutical composition comprising the peptide glu-asp-gly and use for treating helicobacter pylori induced gastroduodenal diseases
11/22/2012WO2012087180A9 Method for treating acute cerebral and spinal blood flow disorders of an ischaemic or haemorrhagic nature
11/22/2012WO2012072715A3 Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
11/22/2012WO2012063237A3 Buffered ophthalmic compositions and methods of use thereof
11/22/2012WO2012041261A3 Peptides from the venom of the rhopalurus junceus scorpion and pharmaceutical composition
11/22/2012WO2012037008A3 Therapy for mll-rearranged leukemia
11/22/2012WO2011095705A3 Novel caspase-14 activator peptides and compositions comprising said peptides
11/22/2012US20120297495 Zinc-finger nuclease and rna interference mediated inactivation of viral genomes
11/22/2012US20120297494 Compositions and methods of treatment of black hemophiliac patients
11/22/2012US20120296443 Sericin extracted fabrics
11/22/2012US20120296403 Methods and compounds for muscle growth
11/22/2012US20120296352 Sericin extracted fabrics
11/22/2012US20120296351 Sericin extracted fabrics
11/22/2012US20120296072 N-terminally chemically modified protein compositions and methods
11/22/2012US20120295855 Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
11/22/2012US20120295854 Methods of Inducing Tissue Regeneration
11/22/2012US20120295853 Neuronal pain pathway
11/22/2012US20120295852 Methods of treating depression and other related diseases
11/22/2012US20120295851 Peptides, compositions and uses thereof
11/22/2012US20120295850 Glp-1 receptor agonists to treat pancreatitis
11/22/2012US20120295849 Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
11/22/2012US20120295848 Sustained-release composition and process for producing the same
11/22/2012US20120295847 Acylated GLP-1 Compounds
11/22/2012US20120295846 Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
11/22/2012US20120295845 Imidazo-pyrazoles as gpr119 inhibitors
11/22/2012US20120295844 Use of aprotinin for treating parasitic infections and prognosing bovine trypanotolerance
11/22/2012US20120295843 Combination therapy for the treatment of hcv infection
11/22/2012US20120295842 Phenanthridine macrocyclic hepatitis c serine protease inhibitors
11/22/2012US20120295841 Sanglifehrin Based Compounds
11/22/2012US20120295840 Treatment of aspergillus infections with alpha thymosin peptides
11/22/2012US20120295839 Method of treatment and prophylaxis of bacterial vaginosis
11/22/2012US20120295837 Novel antimicrobial agents
11/22/2012US20120295836 GLP-I Agonist And Cardiovascular Complications
11/22/2012US20120295835 Sgef controls macular, corpus callosum and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorogenic cell growth
11/22/2012US20120295834 Opioid Prodrugs with Heterocyclic Linkers
11/22/2012US20120295833 Polysaccharides having an adjustable degree of functionalization
11/22/2012US20120295832 Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds
11/22/2012US20120295327 Targeted Therapeutic Proteins
11/22/2012US20120294956 Inhibition of dynamin related protein 1 to promote cell death
11/22/2012US20120294953 Surface Modified Biological Materials
11/22/2012US20120294951 Use of goat serum for veterinary treatment
11/22/2012US20120294936 Reduced mass metformin formulations
11/22/2012US20120294930 Combination of kinase inhibitors and uses thereof
11/22/2012US20120294925 Biomaterial
11/22/2012US20120294924 Peptide-Lipid Conjugates And Uses Thereof
11/22/2012US20120294906 Sericin extracted fabrics
11/22/2012US20120294902 Peptide amphiphiles and methods to electrostatically control bioactivity of the ikvav peptide epitope
11/22/2012US20120294901 Novel cochleate formulations
11/22/2012US20120294898 Injectable dbm for soft tissue repair
11/22/2012US20120294897 Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer
11/22/2012US20120294896 Methods and Compositions for Poxvirus A35R Protein
11/22/2012US20120294895 Protein a compositions and methods of use
11/22/2012US20120294884 Methods of blocking tissue destruction by autoreactive t cells
11/22/2012US20120294882 Modified tuberculosis antigens
11/22/2012US20120294871 Modulation of gpcr-mediated camp production through lrp6 and its therapeutic application
11/22/2012US20120294869 Methods for Treating Fatty Liver Disease
11/22/2012US20120294866 Pharmaceutical formulation for proteins
11/22/2012US20120294855 Glp-1 receptor agonist compounds for obstructive sleep apnea
11/22/2012US20120294854 Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors
11/22/2012US20120294846 Treatment of Pulmonary and Pleural Fibrosis Using HSP27 Inhibitors
11/22/2012US20120294845 Method of making a polymer preferably an (alkyl) acryloyl polycarbonate, the polymer and (alkyl) acryloyl polycarbonate obtained, and a biodevice comprising same
11/22/2012US20120294844 Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions
11/22/2012US20120294843 Caspase inhibitors
11/22/2012US20120294838 Regulation of endogenous gene expression in cells using zinc finger proteins
11/22/2012US20120294832 Composition comprising interferon alpha
11/22/2012US20120294831 Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
11/22/2012US20120294830 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
11/22/2012US20120294829 Liquid formulations for long-acting g-csf conjugate
11/22/2012US20120294826 Methods, kits and compositions for ameliorating adverse effects associated with transfusion of aged red blood cells
11/22/2012US20120294801 Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
11/22/2012US20120294798 Methods of treating cancer using il-21
11/22/2012CA2836643A1 Dry powder vancomycin compositions and associated methods
11/22/2012CA2836637A1 Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells
11/22/2012CA2836599A1 Process for purifying heparan-n-sulfatase
11/22/2012CA2836574A1 Improved peptide pharmaceuticals for insulin resistance
11/22/2012CA2836573A1 Improved peptide pharmaceuticals
11/22/2012CA2836568A1 Immunity induction agent
11/22/2012CA2836556A1 Immunity induction agent
11/22/2012CA2836473A1 Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
11/22/2012CA2836249A1 Method to modulate pigmentation process in the melanocytes of skin
11/22/2012CA2835798A1 Epha4 is a disease modifier in motor neuron disease
1 ... 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 ... 3163